Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis
Last Updated: Tuesday, July 6, 2021
Based on systematic review and meta-analysis data presented during the 2021 American Society of Clinical Oncology Annual Meeting, myelofibrosis patients who received allogeneic hematopoietic cell transplantation experienced overall survival rates of 66.7%, 64.4%, and 55% at 1, 2, and 5 years, respectively, and non-relapse mortality rates of 25.9%, 29.7%, and 30.5%, respectively.
Advertisement
News & Literature Highlights
